However, it remains an open question of how clinicallyrelevant these preclinical findings are (Miles et al, 2010; Blagoev et al, 2013), particularly since there is growing evidence that differential efficacies ofanti-VEGF pathway inhibitors extend to not only disease stage (i.e., primary tumor versus micro- andmacro-metastatic disease) but also among treatment types (i.e., TKIs versus antibodies). This evidence concerns the gene VEGFA and metastatic neoplasm.